Clinical trials: Women With IBS-C
Women With IBS-C
A Single-centre, Randomised, Double-blind, Controlled, Parallel-group Study to Evaluate the Effect of a Fermented Dairy Product on Abdominal Distension, Digestive Symptoms and Rectal Sensitivity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to evaluate the effect of a commercially available fermented dairy product containing probiotics (4 weeks, twice a day) on abdominal distension in IBS patients with constipation (IBS-C).
- Trial name
- NCT01097993
- Testing
- 1-fermented dairy product, 2- milk-based non-fermented dairy product (control product)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
IBS-C and IBS With Mixed Bowel Habits
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
Recent literature has demonstrated that the group of IBS sufferers who experience mixed bowel habits may be more similar to IBS-C patients than IBS-D patients.
- Trial name
- NCT00142987
- Testing
- Tegaserod
- Volunteers
- 664 people
- Sponsor
- Novartis
Constipation-Predominant Irritable Bowel Syndrome
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
The main purpose of this study is to evaluate the long-term safety and tolerability of renzapride at a dose of 4 mg taken once daily for 12 months in women with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT00607971
- Testing
- Renzapride
- Where
- 126 sites in United States
- Volunteers
- 939 people
- Sponsor
- Alizyme
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
- Trial name
- NCT00171431
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Irritable Bowel Syndrome
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
The purpose of the study is to investigate whether renzapride will help alleviate the symptoms associated with constipation predominant irritable bowel syndrome in female patients.
- Trial name
- NCT00268879
- Testing
- Renzapride
- Where
- United Kingdom
- Volunteers
- 1,821 people
- Sponsor
- Alizyme
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation
To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available…
- Trial name
- NCT00511771
- Testing
- Tegaserod
- Sponsor
- Novartis
Constipation-predominant Irritable Bowel Syndrome
Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Irritable Bowel Syndrome (IBS) is a common disorder, defined by symptom-based diagnostic criteria. The pathogenesis is multifactorial and gut motor dysfunction is considered to be a contributing factor.
- Trial name
- NCT01085643
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Cedars-Sinai Medical Center